The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial
Open accessAbstract
Importance: A daily dose with 6 mg of dexamethasone is recommended for up to 10 days in patients with severe and critical COVID-19, but a higher dose may benefit those with more severe disease. Objective: To assess the effects of 12 mg/d vs 6 mg/d of dexamethasone in patients with COVID-19 and severe hypoxemia. Design, Setting, and Participants: A multicenter, randomized clinical trial was conducted between August 2020 and May 2021 at 26 hospitals in Europe and India and included 1000 adults with confirmed COVID-19 requiring at least 10 L/min of oxygen or mechanical ventilation. End of 90-day follow-up was on August 19, 2021. Interventions: Patients were randomized 1:1 to 12 mg/d of intravenous dexamethasone (n = 503) or 6 mg/d of intravenous dexamethasone (n = 497) for up to 10 days. Main Outcomes and Measures: The primary outcome was the number of days alive without life support (invasive mechanical ventilation, circulatory support, or kidney replacement therapy) at 28 days and was adjusted for stratification variables. Of the 8 prespecified secondary outcomes, 5 are included in this analysis (the number of days alive without life support at 90 days, the number of days alive out of the hospital at 90 days, mortality at 28 days and at 90 days, and ≥1 serious adverse reactions at 28 days). Results: Of the 1000 randomized patients, 982 were included (median age, 65 [IQR, 55-73] years; 305 [31%] women) and primary outcome data were available for 971 (491 in the 12 mg of dexamethasone group and 480 in the 6 mg of dexamethasone group). The median number of days alive without life support was 22.0 days (IQR, 6.0-28.0 days) in the 12 mg of dexamethasone group and 20.5 days (IQR, 4.0-28.0 days) in the 6 mg of dexamethasone group (adjusted mean difference, 1.3 days [95% CI, 0-2.6 days]; P = .07). Mortality at 28 days was 27.1% in the 12 mg of dexamethasone group vs 32.3% in the 6 mg of dexamethasone group (adjusted relative risk, 0.86 [99% CI, 0.68-1.08]). Mortality at 90 days was 32.0% in the 12 mg of dexamethasone group vs 37.7% in the 6 mg of dexamethasone group (adjusted relative risk, 0.87 [99% CI, 0.70-1.07]). Serious adverse reactions, including septic shock and invasive fungal infections, occurred in 11.3% in the 12 mg of dexamethasone group vs 13.4% in the 6 mg of dexamethasone group (adjusted relative risk, 0.83 [99% CI, 0.54-1.29]). Conclusions and Relevance: Among patients with COVID-19 and severe hypoxemia, 12 mg/d of dexamethasone compared with 6 mg/d of dexamethasone did not result in statistically significantly more days alive without life support at 28 days. However, the trial may have been underpowered to identify a significant difference. Trial Registration: ClinicalTrials.gov Identifier: NCT04509973 and ctri.nic.in Identifier: CTRI/2020/10/028731.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
Self-citationA Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne, J. A. C., Murthy, S., Diaz, J. V., Slutsky, A. S., Villar, J., Angus, D. C., Annane, D., Azevedo, L. C. P., Berwanger, O., et al. (2020) · JAMA · doi:10.1001/jama.2020.17023 · Cited by 2,257
Self-citationAbani, O., Abbas, A., Abbas, F., Abbas, M., Abbasi, S., Abbass, H., Abbott, A., Abdallah, N., Abdelaziz, A., Abdelfattah, M., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00676-0 · Cited by 1,983
Self-citationInterleukin-6 receptor antagonists in critically ill patients with Covid-19.
The REMAP-CAP Investigators (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100433 · Cited by 1,962
Tomazini, B. M., Maia, I. S., Cavalcanti, A. B., Berwanger, O., Rosa, R. G., Veiga, V. C., Avezum, A., Lopes, R. D., Bueno, F. R., Silva, M. V. A. O., et al. (2020) · JAMA · doi:10.1001/jama.2020.17021 · Cited by 1,241
Villar, J., Ferrando, C., Martínez, D., Ambrós, A., Muñoz, T., Soler, J. A., Aguilar, G., Alba, F., González-Higueras, E., Conesa, L. A., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30417-5 · Cited by 1,199
Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India
Singh, A. K., Singh, R., Joshi, S. R., & Misra, A. (2021) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2021.05.019 · Cited by 1,102
A living WHO guideline on drugs for covid-19 (2020-2023)
Agarwal, A., Hunt, B. J., Stegemann, M., Rochwerg, B., Lamontagne, F., Siemieniuk, R. A., Agoritsas, T., Askie, L., Lytvyn, L., Leo, Y.-S., et al. (2020) · BMJ · doi:10.1136/bmj.m3379 · Cited by 1,041
The Writing Committee for the REMAP-CAP Investigators, Angus, D. C., Derde, L., Al-Beidh, F., Annane, D., Arabi, Y., Beane, A., van Bentum-Puijk, W., Berry, L., Bhimani, Z., et al. (2020) · JAMA · doi:10.1001/jama.2020.17022 · Cited by 855
Self-citation
Cited by
The time toxicity of cancer treatment
Gupta, A., Eisenhauer, E. A., & Booth, C. M. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02810 · Cited by 356
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment
Drożdżal, S., Rosik, J., Lechowicz, K., Machaj, F., Szostak, B., Przybyciński, J., Lorzadeh, S., Kotfis, K., Ghavami, S., & Łos, M. J. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100794 · Cited by 286
Metadata
- Authors
- The COVID STEROID 2 Trial Group, Russell, L., Uhre, K. R., Lindgaard, A. L. S., Degn, J. F., Wetterslev, M., Sivapalan, P., Anthon, C. T., Mikkelsen, V. S., la Porta, L. C., Jensen, T. S., Levin, C. K., Kronborg, G., Krogh-Madsen, R., Plovsing, R. T. R., Brix, H., Schønemann-Lund, M., Valbjørn, L., Lauritzen, S., Koch, E. B., Sørensen, V. O. I., Seitz-Rasmussen, H. E. S., Bestle, F. H., Andersen-Ranberg, N. C., Mortensen, C. B., Derby, C. B., Stormholt, E. R., Cao, Y., Strøm, T. S., Lærkner, E., Gilberg, C., Poulsen, M., Olsen, H. T., Rosenkilde, C., Haberlandt, T., Andersen, L. P. K., Jensen, D. B., Hansen, M. C. K., Aagaard, S. R., Vestergaard, S. R., Bunzel, A.-M. G., Siegumfeldt, R. M., Klitgaard, T. L., Krejberg, K. U., Nielsen, H., Elvira, E., Kumari, H. N., Swaminathan, J., Chander, K. A., Rajan, N. G., Thomas, S., Thomas, A., Odankadummai, V., Antony, A. M., Kulkarni, A. P., Baliga, N., Lodh, N., Vijayakumaran, S. C., Kalvit, K., Sahu, T., Patil, V. P., Kothekar, A. T., Bhosale, S. J., Gorade, M., Shrivastava, A. M., Uddhavrao, J. J., Sharma, R., Mali, J., Niranjan, H. R., Lobo, C., Neve, V., Maurya, D., Salunke, M., Pattanaik, S., Agrawal, A., Hegde, A., Badgurjar, R. K., Jhaveri, B. N., Sarje, D. B., Ananda, H. J., Sen, B., Ambily, C. M., Jose, E. P., Kadam, V., Chiluka, A., Kuril, R., Mathew, E., Shirsekar, S., Kansal, S., Dahiya, R., Thakur, V. K., Tewatia, R., Rawat, S., Tyagi, H., Bhakare, M., Bhise, C., Girme, A., Kunjumon, L. T., Jose, M., Sharma, N., Bali, A., Patel, M., Bhutaka, N., Pathrose, E., Goyal, G., Baby, R., Fernandez, R., Bhattacharya, P. K., Kindo, S., Aaditya, A., Raj, K., Poddar, A., Ansari, A., Alam, M., Khandagale, V., Sarode, S., Garde, S., Shinde, S., Jagtap, N., Khartode, C., Palange, A., Pawar, A., Mulay, M., Pirzade, S., Jagtap, M., Rathod, B., Tanna, D., Chaudhary, K., Deshpande, S., Raj, R., Ambapkar, S., Ambapkar, S., Penurkar, M., Sambare, A., Joshi, R., Kinolkar, B., Shaikh, T. A., Didriksson, H., Jönsson, C., Gagnö, G., Zacharias, D., Jong, M. L., Roth, M., Mader, R., Fazlija, L., Akaltan, M., Eichenberger, A., Rüegg, G., Dill, T., Schoenmaekers, B., Kumar, A., Rajbhandari, D., Arfin, S., Bathla, N., Joshi, R., Kunigari, M., Munch, M. W., Myatra, S. N., Vijayaraghavan, B. K. T., Saseedharan, S., Benfield, T., Wahlin, R. R., Rasmussen, B. S., Andreasen, A. S., Poulsen, L. M., Cioccari, L., Khan, M. S., Kapadia, F., Divatia, J. V., Brøchner, A. C., Bestle, M. H., Helleberg, M., Michelsen, J., Padmanaban, A., Bose, N., Møller, A., Borawake, K., Kristiansen, K. T., Shukla, U., Chew, M. S., Dixit, S., Ulrik, C. S., Amin, P. R., Chawla, R., Wamberg, C. A., Shah, M. S., Darfelt, I. S., Jørgensen, V. L., Smitt, M., Granholm, A., Kjær, M.-B. N., Møller, M. H., Meyhoff, T. S., Vesterlund, G. K., Hammond, N. E., Micallef, S., Bassi, A., John, O., Jha, A., Cronhjort, M., Jakob, S. M., Gluud, C., Lange, T., Kadam, V., Marcussen, K. V., Hollenberg, J., Hedman, A., Nielsen, H., Schjørring, O. L., Jensen, M. Q., Leistner, J. W., Jonassen, T. B., Kristensen, C. M., Clapp, E. C., Hjortsø, C. J. S., Jensen, T. S., Halstad, L. S., Bak, E. R. B., Zaabalawi, R., Metcalf-Clausen, M., Abdi, S., Hatley, E. V., Aksnes, T. S., Gleipner-Andersen, E., Alarcón, A. F., Yamin, G., Heymowski, A., Berggren, A., La Cour, K., Weihe, S., Pind, A. H., Engstrøm, J., Jha, V., Venkatesh, B., & Perner, A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2021-11-09
- Volume
- 326
- Issue
- 18
- Pages
- 1807
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W3206865065
- Cited by
- 253
- References
- 21
- FWCI
- 16.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial. https://app.cochat.ai/papers/10.1001/jama.2021.18295
- The paper
- The COVID STEROID 2 Trial Group, Russell, L., Uhre, K. R., Lindgaard, A. L. S., Degn, J. F., Wetterslev, M., Sivapalan, P., Anthon, C. T., Mikkelsen, V. S., la Porta, L. C., Jensen, T. S., Levin, C. K., Kronborg, G., Krogh-Madsen, R., Plovsing, R. T. R., Brix, H., Schønemann-Lund, M., Valbjørn, L., Lauritzen, S., . . . Perner, A. (2021). Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial. JAMA. https://doi.org/10.1001/jama.2021.18295
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.